Search Results - subject:"Clinical Trial Design"

Learning personalized treatment strategies with predictive and prognostic covariates in adaptive clinical trials

Alban, Andres; Chick, Stephen E.; Zoumpoulis, Spyros I. - 2025 - Revised version of 2024/35/TOM/DSC

Persistent link: https://www.econbiz.de/10015192607

Learning personalized treatment strategies with predictive and prognostic covariates in adaptive clinical trials

Alban, Andres; Chick, Stephen E.; Zoumpoulis, Spyros I. - 2024 - Revised version of 2022/33/TOM/DSC

Persistent link: https://www.econbiz.de/10014550850

How can a joint European health technology assessment provide an "additional benefit" over the current standard of national assessments?

Julian, Elaine; Gianfrate, Fabrizio; de Sola-Morales, Oriol - In: Health Economics Review 12 (2022) 1, pp. 1-12

drivers in HTAs today (scale 1, low to 5, high) were clinical trial design (mean 4.45), right endpoints (mean 4.40), and size …

Persistent link: https://www.econbiz.de/10014489870

Shaping a research agenda to ensure a successful European health technology assessment: Insights generated during the inaugural convention of the European Access Academy

Julian, Elaine; Pavlovic, Mira; de Sola-Morales, Oriol; … - In: Health Economics Review 12 (2022) 1, pp. 1-15

Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...

Persistent link: https://www.econbiz.de/10014489950

How can a joint European health technology assessment provide an "additional benefit" over the current standard of national assessments?

Julian, Elaine; Gianfrate, Fabrizio; Sola-Morales, Oriol de - In: Health economics review 12 (2022) 1, pp. 1-12

drivers in HTAs today (scale 1, low to 5, high) were clinical trial design (mean 4.45), right endpoints (mean 4.40), and size …

Persistent link: https://www.econbiz.de/10013329416

Learning personalized treatment strategies with predictive and prognostic covariates in adaptive clinical trials

Alban, Andres; Chick, Stephen E.; Zoumpoulis, Spyros I. - 2022

Persistent link: https://www.econbiz.de/10013373076

Shaping a research agenda to ensure a successful European health technology assessment : insights generated during the inaugural convention of the European Access Academy

Julian, Elaine; Pavlovic, Mira; Sola-Morales, Oriol de; … - In: Health economics review 12 (2022) 1, pp. 1-15

Persistent link: https://www.econbiz.de/10013492801

Financially adaptive clinical trials via option pricing analysis

Chaudhuri, Shomesh E.; Lo, Andrew W. - In: Journal of econometrics 240 (2024) 2, pp. 1-11

Persistent link: https://www.econbiz.de/10015075136

Is the FDA too conservative or too aggressive? : a Bayesian decision analysis of clinical trial design

Isakov, Leah; Lo, Andrew W.; Montazerhodjat, Vahid - In: Journal of econometrics 211 (2019) 1, pp. 117-136

Persistent link: https://www.econbiz.de/10012303603

Bayesian optimal interval design for phase I oncology clinical trials

Fellman, Bryan M.; Yuan, Ying - In: Stata Journal 15 (2015) 1, pp. 110-120

The Bayesian optimal interval (BOIN) design is a novel phase I trial design for finding the maximum tolerated dose (MTD). With the BOIN design, phase I trials are conducted as a sequence of decision-making steps for assigning an appropriate dose for each enrolled patient. The design optimizes...

Persistent link: https://www.econbiz.de/10011265699